An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs.

Trial Profile

An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 15 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 22 Jan 2016 Protocol has been amended with addition of Ipilimumab as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top